Werewolf Therapeutics Faces Delisting Concerns
Ticker: HOWL · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1785530
| Field | Detail |
|---|---|
| Company | Werewolf Therapeutics, Inc. (HOWL) |
| Form Type | 8-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
TL;DR
Werewolf Therapeutics might get delisted - big trouble brewing.
AI Summary
Werewolf Therapeutics, Inc. filed an 8-K on October 6, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event reported was on October 2, 2025. The company is incorporated in Delaware and its principal executive offices are located in Watertown, Massachusetts.
Why It Matters
This filing indicates potential issues with Werewolf Therapeutics' continued listing on an exchange, which could significantly impact its stock value and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's operations and stock value.
Key Numbers
- 001-40366 — SEC File Number (Identifies the company's filings with the SEC.)
- 82-3523180 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Werewolf Therapeutics, Inc. (company) — Registrant
- October 2, 2025 (date) — Earliest event reported
- October 6, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Watertown, Massachusetts (location) — Principal executive offices
FAQ
What specific listing rule or standard has Werewolf Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that was not met, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the earliest event date reported in this 8-K?
The earliest event reported is October 2, 2025.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted on October 6, 2025.
Where are Werewolf Therapeutics' principal executive offices located?
Werewolf Therapeutics' principal executive offices are located at 200 Talcott Ave, 2nd Floor, Watertown, Massachusetts, 02472.
What is the company's standard industrial classification?
The company's standard industrial classification is Pharmaceutical Preparations [2834].
Filing Stats: 623 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-10-06 16:33:20
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share HOWL The Nasdaq
Filing Documents
- d12663d8k.htm (8-K) — 24KB
- 0001193125-25-231953.txt ( ) — 139KB
- howl-20251002.xsd (EX-101.SCH) — 3KB
- howl-20251002_lab.xml (EX-101.LAB) — 18KB
- howl-20251002_pre.xml (EX-101.PRE) — 11KB
- d12663d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WEREWOLF THERAPEUTICS, INC. Date: October 6, 2025 By: /s/ Timothy W. Trost Timothy W. Trost Chief Financial Officer and Treasurer